Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Inclusion Criteria: Arm 1: * Patients must have unmethylated MGMT supratentorial high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma). Arm 2: * Patients must have supratentorial methylated MGMT high-grade glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed astro oligodendroglioma or glioblastoma). Both: * Patients must have MRI or CT with contrast within 28 days prior to starting treatment. * Patients must have a Karnofsky performance status ≥ 70% (i.e. the patient must be able to care for himself/herself with occasional help from others). * Patients must have adequate blood, kidney and liver function * Patients must be able to provide written informed consent. * Patients and their sexual partners must agree to avoid conception while on the study due to possible risks from experimental drugs. Women will need a negative pregnancy test to be on the study * Patients may not have any other cancers except skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago Exclusion Criteria: * Patients with other serious diseases * Pregnant women * Patients getting other cancer treatments * Patients with other cancers except for localized skin cancer and localized bladder, prostate, cervical, or breast cancer which were cured more than 3 years ago * Patients who have had repeat craniotomy for tumor therapy after receiving radiation therapy and temozolomide treatment. * Patients who have previously received other treatments for their cancers * Patient has previously taken ruxolitinib or is allergic to components of the study drug * Use of blood thinners * Human immunodeficiency virus (HIV) infection * Active hepatitis B or C infection * Heart diseases including abnormal electrocardiogram (EKG) * Patients unwilling or unable to follow this protocol